Table 4 Incremental cost per QALY gained
Treatments ordered from least to most effective | Patient-level | Population-level (100 MDR patients) | Incremental cost per QALY gained (€) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Total cost, € | Total QALYs gained | Total LYG | Total cost, € | Total QALYs gained | Total LYG | Versus BR alone | Versus Linezolid plus BR | Versus delamanid plus BR | |
BR alone | 60,962 | 3.68 | 4.82 | 6,096,152 | 368 | 482 | – | 87,484 | 38,703 |
Linezolid plus BR | 80,460 | 3.91 | 5.07 | 8,045,981 | 391 | 507 | 87,484 | – | 2026 |
Delamanid plus BR | 81,079 | 4.21 | 5.36 | 8,107,888 | 421 | 536 | 38,703 | 2026 | – |
Bedaquiline plus BR | 85,575 | 4.79 | 5.95 | 8,557,529 | 479 | 595 | 22,238 | 5787 | 7774 |